Affiliation: Lund University
- Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trialsCarsten Rose
Department of Oncology, Lund University Hospital, 22185 Lund, Sweden
J Cancer Res Clin Oncol 134:7-17. 2008..The results of these trials have important clinical implications for the future of extended adjuvant hormonal therapy for breast cancer...
- An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozoleC Rose
Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden
Eur J Cancer 39:2318-27. 2003..These results support previous data documenting the greater aromatase-inhibiting activity of letrozole and indicate that advanced breast cancer is more responsive to letrozole than to anastrozole as second-line endocrine therapy...
- Given breast cancer, does breast size matter? Data from a prospective breast cancer cohortAndrea Markkula
Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
Cancer Causes Control 23:1307-16. 2012..The purpose of this study was to elucidate whether breast size independently influenced disease-free survival in breast cancer patients...
- Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphismsSigne Borgquist
Department of Oncology, Clinical Sciences, Skane University Hospital, Lund University, Lund, Sweden
Breast Cancer Res Treat 137:849-62. 2013..ESR2 polymorphisms seem to divide patients into good and poor survivors based on BMI, stressing the need of taking host factors into consideration in the evaluation of prognostic markers...
- Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trialOlöf Bjarnadottir
Department of Oncology, Skane University Hospital, Clinical Sciences, Lund University, SE 221 85, Lund, Sweden
Breast Cancer Res Treat 138:499-508. 2013..Future studies are needed to evaluate HMGCR as a predictive marker for the selection of breast cancer patients who may benefit from statin treatment...
- Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohortAndrea Markkula
Department of Oncology, Skane University Hospital, Lund, Sweden
Cancer Prev Res (Phila) 5:735-45. 2012..97; 95% CI, 1.08-8.15), adjusted for age and tumor characteristics. In conclusion, two clinical profiles predicted early nonadherence and may allow for targeted interventions to increase adherence if validated in an independent cohort...
- A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancerCarsten Rose
Department of Oncology, Lund University Hospital, Lund, Sweden
Am J Clin Oncol 26:S9-16. 2003..Based on favorable results from these trials, letrozole and anastrozole have also been approved for use as first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer...
- Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor statusMaria Simonsson
Department of Oncology, Clinical Sciences, Lund, Lund University, Barngatan 2B, 22185, Lund, Sweden
Cancer Causes Control 24:929-40. 2013..The purpose was to investigate the impact of coffee consumption on tumor characteristics and risk for early events in relation to breast cancer treatment and CYP1A2 and CYP2C8 genotypes...
- Natural remedy use in a prospective cohort of breast cancer patients in southern SwedenMaria Hietala
Department of Oncology, Clinical Sciences, Lund University, Sweden
Acta Oncol 50:134-43. 2011..We studied biologically based CAM use with and without vitamins/minerals in relation to patient and tumor characteristics as well as treatment in an ongoing prospective cohort of 855 primary breast cancer patients...
- Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studiesQuinci Romero
Department of Oncology, Skane University Hospital, Lund, Sweden
BMC Cancer 11:341. 2011..Also, a lack of consensus concerning Ki67 assessment may raise problems in the comparison of neo-adjuvant studies. Thus, the secondary aim was to present a novel model for Ki67 assessment...
- Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor statusErika Bågeman
Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden
Cancer Epidemiol Biomarkers Prev 17:895-901. 2008..2; 95% confidence interval, 1.9-9.3; P = 0.0002). These findings raise the hypothesis that coffee slows the growth of ER-positive tumors in patients with CYP1A2*1F A/A and may have implications for breast cancer if confirmed...
- A systematic overview of radiation therapy effects in breast cancerLars Erik Rutqvist
Department of Oncology, Huddinge University Hospital, Stockholm, Sweden
Acta Oncol 42:532-45. 2003..There is insufficient evidence to define the optimal integration of systemic adjuvant therapy and postoperative radiotherapy. There are limited data on radiotherapy-related morbidity in breast cancer. No conclusions can be drawn...
- CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patientsH Jernstrom
Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund SE 221 85, Sweden
Br J Cancer 101:1817-23. 2009..We aimed to investigate the frequency of CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival...
- Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous womenE Bågeman
Department of Oncology, Clinical Sciences, Lund University, SE 221 85 Lund, Sweden
Br J Cancer 96:712-7. 2007..006). Multiparity combined with IGF1-19/-19 was associated with an early age at breast cancer diagnosis. If confirmed, IGF1-19/-19 may help identify a subgroup of women for earlier breast cancer screening...
- Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex
Department of Medical Oncology, 452 Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands, and Department of Oncology, Lund University Hospital, Sweden
Eur J Cancer 42:3178-85. 2006..Furthermore it was postulated that alternating tamoxifen with a non-cross resistant endocrine modality could (further) postpone hormone resistance...
- [Natural remedies and hormone preparations--potential risk for breast cancer patients. A study surveys the use of agents which possibly counteract with the treatment]Farnaz Malekzadeh
Lakartidningen 102:3226-8, 3230-1. 2005..In conclusion, it is important that doctors discuss the use of CAM and exogenous hormone therapy with their breast cancer patients given the prevalence of these drugs...
- The responsiveness of a tumour to any kind of therapy is reflected by the objective response rateCarsten Rose
Eur J Cancer 40:2859. 2004
- Challenges in the endocrine management of breast cancerHenning T Mouridsen
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Breast 12:S2-19. 2003..These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions..
- Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidenceAnita Ringberg
Int J Cancer 119:2242-3; author reply 2244. 2006
- "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilersPatrik Edén
Complex Systems Division, Department of Theoretical Physics, Lund University, Solvegatan 14A, SE 22362 Lund, Sweden
Eur J Cancer 40:1837-41. 2004..Our analysis suggests that it might be possible to improve the combination of different conventional prognostic markers into one prognostic index...
- Cosmetic outcome and breast morbidity in breast-conserving treatment--results from the Danish DBCG-82TM national randomized trial in breast cancerJørgen Johansen
Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus
Acta Oncol 41:369-80. 2002....